Uterine Cancer pp 425-435 | Cite as

Hormone Therapy in Normal Postmenopausal Women and After Treatment for Endometrial Cancer

  • Nilanchali Singh
  • Shalini Rajaram
  • Neerja Goel


About 20–25 % of women with endometrial carcinomas are diagnosed premenopausaly [1]. Hysterectomy and bilateral salpingo-oophorectomy the obligatory operative therapy, results in surgically induced menopause. The abrupt loss of estrogen gives rise to deficiency symptoms, mainly hot flushes, sleep disorders, and depressive mood, reducing quality of life. Hormone therapy (HT) has been used for decades to improve quality of life of menopausal women by reducing menopausal symptoms. The role of hormone therapy in women with endometrial cancer and risk of endometrial cancer in women on hormones will be discussed in this chapter.


Hormone Therapy Endometrial Cancer Endometrial Carcinoma National Comprehensive Cancer Network Estrogen Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Mueck AO, Seeger H. Hormone therapy after endometrial cancer. Endocr Relat Cancer. 2004;11:305–14.CrossRefPubMedGoogle Scholar
  2. 2.
    Crosignani PG. Effects of hormone replacement therapy. Int J Fertil. 1992;37 Suppl 2:98–103.PubMedGoogle Scholar
  3. 3.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Beral V. Breast cancer and hormone- therapy in the Million Women Study. Lancet. 2003;362(9382):419–27.CrossRefPubMedGoogle Scholar
  5. 5.
    Langer RD, Manson JE, Allison MA. Have we come full circle – or moved forward? The Women’s Health Initiative 10 years on. Climacteric. 2012;15(3):206–12.CrossRefPubMedGoogle Scholar
  6. 6.
    Oehler MK, Brand A, Wain GV. Molecular genetics and endometrial cancer. J Br Menopause Soc. 2003;9:27–31.CrossRefPubMedGoogle Scholar
  7. 7.
    Romer T, Mueck AO. Endometrium und hormone substitution. Stuttgart: Georg Thieme Verlag; 1998.Google Scholar
  8. 8.
    Seeger H, Wallwiener D, Mueck AO. Comparison of the effect of progesterone, medroxyprogesterone acetate and norethisterone on the proliferation of human breast cancer cells. J Br Menopause Soc. 2003;9:36–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Jane FM, Davis SR. A practitioner’s toolkit for managing the menopause. Climacteric. 2014;17:1–16.CrossRefGoogle Scholar
  10. 10.
    Sturdee DW. Are progestins really necessary as part of a combined HRT regimen? Climacteric. 2013;16 Suppl 1:79–84.CrossRefPubMedGoogle Scholar
  11. 11.
    Clavel-Chapelon F, van Liere MJ, Giubout C, Niravong MY, Goulard H, Le Corre C, et al. E3N, a French cohort study on cancer risk factors. E3N group. Eur J Cancer Prev. 1997;6(5):473–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Panay N, Hamoda H, Arya R, Savvas M. British Menopause Society & Women’s Health Concern recommendations on hormone therapy. Menopause Int. 2013;19(2):59–68.PubMedGoogle Scholar
  13. 13.
    Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin study follow-up (HERS II). JAMA. 2002;288:58–66.CrossRefPubMedGoogle Scholar
  14. 14.
    Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol. 2014;142:83–9.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Feeley K, Wells M. Hormone therapy and the endometrium. J Clin Pathol. 2001;54(6):435–40.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin therapy and endometrial cancer. J Natl Cancer Inst. 1997;89:1110–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Lacey JV, Leitzmann MF, Chang SC, et al. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health study cohort. Cancer. 2007;109:1303–11.CrossRefPubMedGoogle Scholar
  18. 18.
    Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen with and without progestins. J Natl Cancer Inst. 1999;91:1131–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Jaakkola S, Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer. 2011;128(7):1644–51.CrossRefPubMedGoogle Scholar
  20. 20.
    Razavi P, Pike MC, Horn-Ross PL, Templeman C, Bernstein L, Ursin G. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:475–83.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Lacey JV, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2005;14:172–31.CrossRefGoogle Scholar
  22. 22.
    Grady D, Gebretsadik T, Kerlikowski K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304–15.CrossRefPubMedGoogle Scholar
  23. 23.
    Hill DA, Weiss NS, Beresford SAA, Voigt LF, Daling JR, Stanford JL, Self S. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol. 2000;183:1456–61.CrossRefPubMedGoogle Scholar
  24. 24.
    Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 1999;10:253–60.CrossRefPubMedGoogle Scholar
  25. 25.
    Lee SJ, Yeo SG, Kang SB, Park DC. Attitudes and practices of Korean gynecologists forwards hormone replacement therapy inendometrial cancer survivors. Eur J Gynaecol Oncol. 2013;34(6):513–7.PubMedGoogle Scholar
  26. 26.
    National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. Uterine neoplasms V.1.2010. Fort Washington: NCCN; 2010.Google Scholar
  27. 27.
    de Villiers TJ, Gass MLS, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Global consensus statement on menopausal hormone therapy. Climacteric. 2013;16:203–4.CrossRefPubMedGoogle Scholar
  28. 28.
    The North American Menopause Society. The hormone therapy position statement of the North American menopause society. Menopause. 2012;19(3):257–71.Google Scholar
  29. 29.
    American College of Obstetricians and Gynecologists (ACOG). Hormone replacement therapy in women treated for endometrial cancer. Committee opinion 235. Int J Gynecol Obstet. 2001;73:283–4.CrossRefGoogle Scholar
  30. 30.
    Creasman WT. HRT and women who have had breast or endometrial cancer. J Epidemiol Biostat. 1999;4:217–25.PubMedGoogle Scholar
  31. 31.
    Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol. 1990;36:189–91.CrossRefPubMedGoogle Scholar
  32. 32.
    Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol. 1996;175:1195–200.CrossRefPubMedGoogle Scholar
  33. 33.
    Suriano KA, McHale M, McLaren CE, Li KF, Re A, DiSaja PJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol. 2001;97:955–60.CrossRefGoogle Scholar
  34. 34.
    Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, Finck G, Pierson N, Pisansky T. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 1998;82:1784–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Farish E, Barnes JF, O’Donoghue F, Fletcher CD, Ekevall K, Hart DM. The role of megestrol acetate as an alternative to conventional hormone replacement therapy. Climacteric. 2000;3:125–34.CrossRefPubMedGoogle Scholar
  36. 36.
    Mirkin S, Archer DF, Taylor HS, Pickar JH, Komm BS. Differential effects of menopausal therapies on the endometrium. Menopause. 2014;21(8):899–908. [Epub ahead of print].CrossRefPubMedGoogle Scholar
  37. 37.
    Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007;92(3):911–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), the physiological and a highly efficient treatment of vaginal atrophy. Menopause. 2009;16(5):907–12.CrossRefPubMedGoogle Scholar
  39. 39.
    Kulak Jr J, Ferriani RA, Komm BS, Taylor HS. Tissue selective estrogen complexes (TSECs) differentially modulate markers of proliferation and differentiation in endometrial cells. Reprod Sci. 2013;20(2):129–37.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Mueck AO, Seeger H, Haasis R, Gohlke-Ba¨rwolf C, Schieber M, Schuchert A, Meinertz T. Effect of oral vs. transdermal estradiol on cGMP during exercise in women with coronary artery disease—randomized, double-blind, placebo-controlled cross over study. Circulation. 1999;100(18):1386.insert last page.Google Scholar
  41. 41.
    Guttuso T, Kurlan R, McDermott MP, Kieburtz K. Gabapentin’s effects on hot flashes in postmenopausal women: a randomised controlled trial. Obstet Gynecol. 2003;101:337–45.CrossRefPubMedGoogle Scholar
  42. 42.
    Johnson EB, Muto MG, Yanushpolsky EH, Mutter GL. Phytoestrogen supplementation and endometrial cancer. Obstet Gynecol. 2001;98:947–50.CrossRefPubMedGoogle Scholar
  43. 43.
    Quaas AM, Kono N, Mack WJ, Hodis HN, Felix JC, Paulson RJ, Shoupe D. Effect of isoflavone soy protein supplementation n endometrial thickness, hyperplasia, andendometrial cancer risk in postmenopausal women: a randomized controlled trial. Menopause. 2013;20(8):840–4.PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Graziottin A. Loss of libido in the postmenopause. Menopausal Med. 2000;8(1):9–12.Google Scholar
  45. 45.
    Chughtai B, Levin R, De E. Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin. Clin Interv Aging. 2008;3(3):503–9.PubMedCentralPubMedGoogle Scholar
  46. 46.
    Van Der Laak JA, De Bie LM, De Leeuw H, De Wilde PC, Hanselaar AG. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol. 2002;55:446–51.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2015

Authors and Affiliations

  • Nilanchali Singh
    • 1
  • Shalini Rajaram
    • 1
  • Neerja Goel
    • 1
  1. 1.Department of Obstetrics & GynecologyUniversity College of Medical Sciences and Guru Teg Bahadur HospitalDelhiIndia

Personalised recommendations